Storing GLP-1 correctly isnt just about convenienceit directly affects how well the medication works
In clinical data to date, retatrutide has shown marginally greater weight loss (~24.2% at 48 weeks in Phase 2) compared to Mounjaro (~22.5% at 72 weeks in Phase 3)
Long-term follow-up data from cardiovascular outcomes trials indicate that any early increase in retinopathy events tends to plateau over time, and the overall trajectory of retinal health may ultimately be favorable due to sustained improvements in glycemic control
for example, highest-risk members in tier 1 could be covered with a $0 copay, while slightly lower-risk members in tier 3 could have some coverage but a greater copay
GLP-1 medications offer real benefits for weight and blood sugar management but those benefits should not come at the cost of bone density, muscle function, or immune health
Intestinal factors in the control of insulin secretion